INTRODUCTION
Lantibiotics are small post-translationally modified peptides with antimicrobial activity, which are produced by Gram-positive bacteria (Chatterjee et al., 2005; McAuliffe et al., 2001; Sahl and Bierbaum, 1998) . In general, this class of bacteriocins is characterized by the presence of the unusual dehydrated amino acids 2,3-didehydroalanine (Dha) and/or 2,3-didehydrobutyrine (Dhb). With neighboring cysteine residues, Dha and Dhb can respectively form thioether-linked lanthionine and 3-methyllanthionine bridges (Guder et al., 2000; Nagao et al., 2006) .
Two major types of lantibiotics have been identified (Jung, 1991) . Type A lantibiotics, such as nisin (Kuipers et al., 1993; Siegers et al., 1996) , epidermin (Peschel and Gotz, 1996) , and Pep5 (Meyer et al., 1995) are flexible, elongated, amphipathic molecules with a positive charge. They usually act by forming pores in the cytoplasmic membrane of a sensitive target organism in processes that may involve other molecules, like the cell wall precursor lipid II (Breukink et al., 1999; Wiedemann et al., 2001) . In contrast, type B lantibiotics, such as cinnamycin (Fredenhagen et al., 1990) and mersacidin (Chatterjee et al., 1992) are globular, conformationally defined peptides that inhibit enzyme functions. Type A lantibiotics are further subdivided into type AI and AII lantibiotics on the basis of their structure; type AI lantibiotics are linear while type AII lantibiotics are globular at the C-terminal region. Type A lantibiotics are usually synthesized with an N-terminal leader peptide. Subsequently, they are translocated across the membrane by an ABC transporter. During membrane translocation the leader peptide is either cleaved by a protease domain of the ABC transporter, or by a separate protease (Guder et al., 2000) . The leader sequences are thought to prevent lantibiotic activation prior to membrane translocation (Chakicherla and Hansen, 1995; van der Meer et al., 1994) .
The sequenced Bacillus subtilis strain 168 is known to produce an extremely stable lantibiotic named sublancin 168, which exhibits bactericidal activity against other Grampositive bacteria, including important pathogens such as Bacillus cereus, Streptococcus pyogenes, and Staphylococcus aureus (Paik et al., 1998; Stein, 2005) . Sublancin 168 was classified as a type AII lantibiotic, although it displayed the, for lantibiotics, extraordinary characteristic of having two disulfide bonds in addition to a -methyllanthionine bridge (Paik et al., 1998) . The gene encoding sublancin 168, named sunA, was identified by sequencing the SP prophage region of the B. subtilis 168 chromosome (Lazarevic et al., 1999) . SunA is transcribed into a monocistronic mRNA (Serizawa et al., 2005) . An operon of four successive genes (sunT, bdbA, yolJ, and bdbB) was found to be located downstream of sunA (Serizawa et al., 2005) . The sunT gene, immediately downstream of sunA, encodes a bifunctional ABC transporter with an ATP-binding cassette domain and a proteolytic domain (McAuliffe et al., 2001) . SunT is indispensable for sublancin 168 production. This ABC transporter is therefore thought to be required for sublancin 168 export from the cytoplasm and concomitant removal of the leader peptide (Dorenbos et al., 2002) . The bdbA and bdbB genes encode thiol-disulfide oxidoreductases. Whereas BdbA is dispensable for sublancin 168 production, BdbB is of major importance for this process (Bolhuis et al., 1999; Dorenbos et al., 2002; Kouwen et al., 2007) . A possible role of the yolJ gene in sublancin 168 production has not yet been documented.
Any bacterium producing a bacteriocin must be immune to its bactericidal activity. To date, two general mechanisms for bacteriocin producer immunity have been reported. Firstly, dedicated ABC transporters of the LanFEG type can actively pump bacteriocins out of the membrane thereby preventing their accumulation to toxic levels (Klein and Entian, 1994; McLaughlin et al., 1999; Peschel and Gotz, 1996; Rince et al., 1997; Otto et al., 1998; Okuda et al., 2008; Stein et al., 2004) . Secondly, the bacterial cell can employ dedicated small producer immunity proteins of the LanI type that are usually weakly associated with the extra-cytoplasmic membrane surface. Such immunity proteins bind specific lantibiotics to intercept them before they can cause cell damage (Kuipers et al., 1993; Saris et al., 1996; Siegers and Entian, 1995; Hoffmann et al., 2004; Stein et al., 2005; Stein et al., 2003) . An alternative type of producer immunity protein, NukH, was more recently described (Okuda et al., 2005; Okuda et al., 2008) . Although the function of NukH resembles that of LanI, its topology is very different since NukH is a membrane protein with three transmembrane domains. In addition to these active immunity mechanisms, cells can also achieve resistance against lantibiotics by modifying the charge of the cell wall or cytoplasmic membrane. For example the D-alanylation of teichoic acids or the lysinylation of phospholipids will, respectively, make the cell wall or membrane more positively charged (Peschel et al., 1999; Peschel and Collins, 2001) . As a consequence, bacterial cells with such modifications will be more resistant to cationic bacteriocins than cells lacking these modifications.
Recent studies by Butcher and Helmann have shown that the yqeZ and yqfAB genes of the W regulon confer resistance to sublancin 168 (Butcher and Helmann, 2006) . However, full producer immunity to sublancin 168 is known to require gene functions of the SP prophage (Hemphill et al., 1980) , while none of the W regulon genes implicated in sublancin 168 resistance are located on this prophage. Thus, it has remained unclear which SP gene or genes are required for sublancin 168 producer immunity. Notably, our previous studies have shown that the ABC transporter SunT, the thiol-disulfide oxidoreductases BdbA and BdbB, and the YolJ protein of unknown function are fully dispensable for sublancin 168 producer immunity (Dorenbos et al., 2002) . Moreover, none of the 187 SP genes show homology to known bacteriocin producer immunity genes (Lazarevic et al., 1999) .
In the present studies, we have addressed the question which SP gene or genes are required for sublancin 168 producer immunity. Our results show that only one of the 187 genes of the SP prophage, yolF, is both required and sufficient for immunity of B. subtilis to sublancin 168. We therefore propose to change the name of this gene to sunI. Interestingly, SunI (YolF) seems to belong to a new class of bacteriocin producer immunity proteins.
RESULTS

YolF is indispensable for sublancin 168 producer immunity
To identify which gene(s) on the SP prophage would confer sublancin 168 producer immunity, growth inhibition assays were performed in which strains potentially producing sublancin 168 were spotted onto a lawn of sensitive or immune indicator cells (Fig. 1) . The applicability of this assay was demonstrated in the following series of base line experiments. First, B. subtilis 168 was used both as an indicator strain and as a producing strain. No zone of growth inhibition was formed around the spotted B. subtilis 168 cells, confirming that this strain is resistant to the sublancin 168 it produces ( Fig 1A) .
Next, we confirmed that the B. subtilis SP strain was not able to grow in the vicinity of the sublancin 168-producing parental strain 168 ( Fig. 1A ). In this case, a clear zone of growth inhibition was visible around the spot of B. subtilis 168 cells. Additionally, using a sunA strain, we confirmed that growth inhibition of the plated SP strain was strictly dependent on the presence of an intact copy of the sunA gene for sublancin 168 in the spotted cells ( Fig. 1A) . Conversely, the producer immunity to sublancin 168 did not depend on the sunA gene, as no zone of growth inhibition was visible when B. subtilis sunA was used as indicator strain and the parental strain 168 was used as sublancin 168 producing strain ( Fig. 1A) . Taken together, these findings demonstrate that the sunA gene is responsible for the observed growth inhibition of cells lacking the SP prophage, and that this gene does not play a role in sublancin 168 producer immunity. Furthermore, these findings also imply that a mutant strain lacking the gene(s) responsible for sublancin 168 immunity will only be viable in a sunA background. For this reason, all mutants that were constructed to identify determinants for sublancin producer immunity also lacked the sunA gene.
As a first approach to identify the sublancin 168 immunity gene(s), two deletion mutants named ANC1 and ANC2 were constructed. These strains lacked, respectively, 23 and 9 SP genes, including the sublancin 168 locus. Sublancin 168 sensitivity of the ANC1 and ANC2 strains was tested by using them as indicator strains and the parental strain B. subtilis 168 as the sublancin 168 producing strain. As shown in Fig. 1B , neither the ANC1 strain, nor the ANC2 strain was able to grow in the vicinity of B. subtilis 168, showing that both strains were sensitive to sublancin 168. This suggested that at least one of the 9 genes deleted in the ANC2 strain was required for sublancin 168 producer immunity. As the five genes in the sublancin 168 locus (sunA, sunT, bdbA, yolJ and bdbB) were already known to be dispensable for sublancin 168 producer immunity ((Dorenbos et al., 2002) ; this study), we focused attention on possible roles of the four remaining deleted genes of B. subtilis ANC2 (i.e. yolC, yolD, uvrX and yolF) in immunity against sublancin 168. To narrow down the possibilities, BlastP analyses with the four respective amino acid sequences were performed to identify proteins of B. subtilis with potentially similar or overlapping functions. This revealed that YolC has a B. subtilis homologue named YozM (91% identical residues and conservative replacements in a stretch of 111 residues), that YolD has a B. subtilis homologue named YozL (92% identical residues and conservative replacements in 97 residues), and that UvrX has three B. subtilis homologues, namely YobH (98% identical residues and conservative replacements in 201 residues), YqjW (59% identical residues and conservative replacements in 414 residues) and YozK (98% identical residues and conservative replacements in 115 residues). In contrast, no protein was identified with a high degree of similarity to YolF. The protein with the highest similarity Strains to be tested for sublancin 168 production were spotted on a lawn of indicator cells. The names of strains spotted to test for sublancin production are listed above the plate images. Names of the strains plated as indicators for sublancin sensitivity/immunity are listed below the plate images. (B) Sublancin immunity assays and schematic representation of deleted SP prophage genes. The names of strains spotted to test for sublancin production are listed above the plate images. Names of the strains plated as indicators for sublancin sensitivity/immunity are listed below the plate images. SP genes are indicated by arrows. The dashed lines indicate the respective parts of the SP region that were deleted to construct the ANC1, ANC2, ANC3 and sunA-yolF strains. Potential transcriptional terminators are indicated as "balls on sticks" (Serizawa et al., 2005). to the YolF sequence is YnzG, both proteins sharing merely 51% identical residues and conservative replacements in a stretch of 68 residues. It is however noteworthy that the ynzG gene lies in an operon containing a gene for a delta endotoxin homologue, suggesting a potential role in the handling of this toxin. We therefore focused attention on a possible role of yolF in sublancin 168 producer immunity. For this purpose, we constructed the B. subtilis ANC3 strain by deletion of the five genes of the sublancin locus plus yolF, as well as the B. subtilis sunA-yolF strain. As shown in Fig. 1B , neither the ANC3 strain nor the sunA-yolF strain were able to grow in the vicinity of the B. subtilis 168 strain ( Fig. 1B) , showing that both strains are sensitive to sublancin 168. Furthermore, consistent with the applied approach of nested gene deletions, neither the ANC1, ANC2, ANC3 nor the sunA-yolF strain produced active sublancin 168 ( Fig. 1B) . Taken together, these results demonstrate that yolF is indispensable for the producer immunity of B. subtilis 168 against sublancin 168.
YolF is sufficient to confer sublancin 168 immunity
Since yolF was identified as being necessary for sublancin 168 producer immunity, we addressed the question whether it was also sufficient to confer immunity to the sublancin 168 sensitive SP strain. Notably, the SP strain does not contain any genes of the SP prophage that could encode a YolF partner protein involved in sublancin 168 producer immunity. Therefore, we expressed the yolF gene ectopically in B. subtilis SP using the promoter of the erythromycin resistance gene on the B. subtilis expression vector pGDL48. Genes placed under control of this promoter are usually expressed constitutively and at moderate levels, which precludes excessive overproduction of the respective gene product. The resulting plasmid was named pGDL-yolF. A negative control plasmid, containing the yolF gene in the opposite orientation, was named pGDL-yolF C . Interestingly, B. subtilis SP pGDL-yolF used as an indicator strain was fully resistant to the sublancin 168 producing strain 168 (Fig. 2) . In contrast, B. subtilis SP pGDL-yolF C was as sensitive for the sublancin 168 produced by strain 168 as the B. subtilis SP strain (Fig. 2) . Taken together, these results show that the yolF gene is not only necessary, but also sufficient to confer immunity to sublancin 168. Next, we verified these findings by growing the B. subtilis strains SP , SP pGDL-yolF and the parental strain 168 in liquid medium containing 90% of spent LB medium that was derived from an overnight culture with B. subtilis 168 (Fig. 3A ). In this spent medium, B. subtilis 168 was growing slightly slower than in fresh LB medium (data not shown). Importantly, the B. subtilis SP strain was unable to grow in the spent medium of B. subtilis 168, whereas the B. subtilis SP pGDL-yolF strain did grow in this medium. This shows that the pGDL-yolF plasmid confers sublancin 168 immunity to B. subtilis SP . Nevertheless, growth of the B. subtilis SP pGDL-yolF strain on spentmedium of strain 168 was slightly slower than that of the parental strain 168. As demonstrated by Western blotting with specific antibodies against YolF, this reduced growth rate in sublancin 168-containing medium might be due to the fact that the pGDL-yolF plasmid directs a slightly lower level of YolF production than the chromosomal yolF gene of the parental strain 168, especially in the exponential growth phase ( Fig. 3B ). Samples were taken at 2.5 hours (t = -2.5) and 1 hour (t = -1) prior the transition point between exponential and post-exponential growth (t = 0) or 1 hour after the transition point (t = 1). Cell lysates were prepared and equal amounts of each lysate were separated by SDS-PAGE. YolF was detected by immunoblotting with specific antibodies against YolF. The position of YolF is indicated by an arrow. An additional band that cross-reacted with the YolF antibody is marked "X", and can be regarded as an internal standard for sample loading. As an ultimate test for the sublancin 168 immunity function of YolF, we performed co-culturing and competition experiments in liquid medium. Firstly, the sublancin 168 producing B. subtilis strain 168 amyE::pX (Cm R ) was used to inoculate growth medium in a 1:1 ratio with the non-producing B. subtilis strain SP amyE::pXTC (Tc R ) with or without pGDL-yolF. The results of co-cultivation and subsequent transfer of samples to plates containing either chloramphenicol or tetracycline showed that the SP strain, which does not produce YolF, was able to survive only for a few hours in the presence of the sublancin 168 producing strain (Fig. 4A) . In contrast, the SP strain producing YolF from the pGDL-yolF plasmid was not inhibited by the deleterious effects of the strain producing sublancin 168 ( Fig. 4B) . Notably, the observed growth of the B. subtilis SP pGDL-yolF strain was slightly slower than that of the parental strain 168, as was observed in the experiment shown in Figure 3 . Secondly, to rule out the possibility that YolF might require other B. subtilis proteins to fulfill its function in sublancin 168 immunity, we introduced the yolF gene into a bacterium that is naturally sensitive to sublancin 168, namely Staphylococcus aureus. For this purpose, the B. subtilis strain 168 amyE::pX (Cm R ) was used to inoculate growth medium in a 1:1 ratio with the S. aureus strain RN4220 containing either the pGDL-yolF plasmid (Km R ) or the pMAD control plasmid (Em R ). The results of these co-cultivation experiments confirmed that S. aureus RN4220 lacking the yolF gene was only able to survive for a few hours in the presence of the sublancin 168 producing B. subtilis strain (Fig. 4C) . In contrast, the introduction of pGDL-yolF allowed S. aureus RN4220 to grow in the presence of B. subtilis 168 ( Fig. 4D ). Taken together, these findings show conclusively that yolF is both essential and sufficient for sublancin 168 immunity.
Localization of YolF
YolF is a small basic protein (pI 9.2) of 105 amino acids (12.1 kDa). To predict the localization of YolF, we first employed the SignalP 3.0 algorithm that identifies potential signal peptides for protein export from the cytoplasm (http://www.cbs.dtu.dk/services/). Although both Neural Network (NN) and Hidden Markov Model (HMM) algorithms in SignalP 3.0 resulted in a positive signal peptide prediction, the signal peptidase cleavage sites predicted by these algorithms differed (NN: cleavage between amino acid 21 and 22; HMM: cleavage between amino acid 26 and 27). Furthermore, the predicted signal peptidase cleavage sites in YolF (NN: VFL-N; HMM: RYS-F) differed considerably from the consensus signal peptidase cleavage sites in known signal peptides of B. subtilis (AXA-A; (Tjalsma and van Dijl, 2005) ). It therefore appeared more likely that YolF would be synthesized with an N-terminal transmembrane domain. Accordingly, predictions for transmembrane domains were conducted using the Topcons server (http://topcons.net). The SCAMPI, PRODIV, and PRO algorithms identified one potential N-terminal transmembrane domain between amino acids 3 and 23. The OCTOPUS algorithm identified an N-terminal transmembrane domain from residues 2 to 22. Furthermore, the MEMSAT3 algorithm (http://bioinf.cs.ucl.ac.uk/memsat/) predicted an N-terminal domain from residues 3 to 21. All these algorithms predicted that the YolF protein would have a N out -C in topology. To verify this prediction, we also applied two other algorithms, namely PrediSi (http://www.predisi.de/) which predicts signal peptides, and Phobius (http://phobius.cgb.ki.se) which discriminates between signal peptides and transmembrane domains. The predictions thus obtained supported the view that YolF does not have a cleavable signal peptide. Furthermore, Phobius indicated an N-terminal transmembrane domain between amino acids 6 and 25 with a N out -C in topology. Taken together, these predictions strongly suggested that YolF is a membrane protein with one N-terminal transmembrane domain, the bulk of the protein facing the cytoplasm. Consistent with our predictions, YolF was recently identified as a membraneassociated protein in a study on the composition of the B. subtilis membrane proteome (Dreisbach et al., 2008) . To verify the localization of YolF in the membrane, we separated the proteins in the growth medium, cytoplasm, membrane and cell wall of B. subtilis 168 and, subsequently, analyzed the presence of YolF by SDS-PAGE and immunoblotting with specific antibodies. The results clearly show that YolF is predominantly located in the membrane of B. subtilis (Fig. 5 ). Additionally, a small portion of the YolF protein was found in the cell wall fraction. However, this is most likely the result of some protoplast lysis during the fractionation procedure since a similar observation was made for the control membrane proteins BdbD and SipS, and the cytoplasmic protein TrxA. By contrast, the secreted control protein LipA was exclusively detected in the growth medium fraction (Fig. 5) .
To investigate the orientation of YolF in the membrane, we used a recently developed procedure based on the membrane impermeability of the thiol-specific crosslinking reagent 4-acetamido-4' -maleimidyl-stilbene-2,2' -disulfonate (AMS) (Facey et al., 2007) . Since AMS is unable to cross the membrane, it can only be cross-linked to reduced cysteine residues on the extracytoplasmic side of the cell. The YolF protein possesses one cysteine residue, predicted to be located in the cytoplasm just behind the transmembrane domain at amino acid position 31. Therefore, we incubated cells from an overnight culture with AMS and monitored AMS binding to YolF via non-reducing SDS-PAGE. The results showed that the cysteine residue of YolF was accessible to AMS only when the cells were disrupted (Fig. 6 ). In protoplasts with an intact membrane, no YolF labeling with AMS could be observed. Similar AMS labeling results were obtained for the cytoplasmic control protein thioredoxin A (TrxA), which has two cysteine residues that are mainly present in a reduced state (Hochgrafe et al., 2005) . In contrast, a fraction of the extracytoplasmic control protein BdbD was labeled with AMS even when the cytoplasmic membrane was intact. It should be noted that no complete AMS labeling of BdbD is possible due to the fact that this protein is an oxidase with two cysteine residues that are disulfide bonded in the majority of molecules; only a fraction of BdbD becomes reduced as part of the catalytic cycle (Kouwen et al., 2007) . Taken together, these observations show that the cysteine residue of YolF behaves like a cytoplasmic cysteine residue. It thus seems that YolF is indeed a membrane protein with an N out -C in topology, the bulk of the protein facing the cytoplasmic compartment. Figure 6 . Topology of YolF. Wild-type B. subtilis 168 cells were grown overnight and collected by centrifugation. Next, equal amounts of cells were protoplasted in either the absence of the thiol-specific cross-linking reagent AMS, in the presence of AMS, or in the presence of AMS and 1% triton X-100. Notably, addition of triton X-100 results in protoplast lysis and, consequently, AMS-labeling of all proteins containing reduced cysteine residues. After washing, protoplasts were lysed and subjected to non-reducing SDS-PAGE to separate proteins with and without bound AMS. Subsequently, proteins were transferred onto nitrocellulose membranes and used for immunodetection with specific antibodies raised against YolF, TrxA, or BdbD. The two stripes mark fast migrating protein species without bound AMS and slow migrating protein species with bound AMS. Additional bands that cross-reacted with the TrxA, BdbD or YolF antibodies are indicated by "X". C, control protoplasts without AMS labeling; I, AMS-labeled intact protoplasts; B, AMS-labeled protoplasts broken with triton X-100.
DISCUSSION
The present studies were aimed at identifying which B. subtilis 168 genes are responsible for producer immunity against the lantibiotic sublancin 168. By systematically narrowing down the chromosomal region that was known to contain the respective gene(s), we were able to pin-point one gene, named yolF, as the sublancin 168 producer immunity gene. Furthermore, we were able to show on plates and in liquid cultures that yolF is both required and sufficient to confer immunity against active sublancin 168, even in a heterologous host. We therefore propose to rename yolF to sunI for sublancin immunity. In silico analyses, sub-cellular fractionation and AMS cross-linking studies indicate that the SunI protein is anchored to the membrane with a single N-terminal membrane-spanning domain that has a N out -C in topology. Thus, the bulk of the protein faces the cytoplasmic compartment of the cell. Such properties have not yet been reported for known bacteriocin immunity proteins. This implies that SunI belongs to a novel class of bacteriocin antagonists.
Sublancin 168 has a broad spectrum of bactericidal activity against Gram-positive bacteria, including staphylococci, streptococci and even other B. subtilis strains. Since its first discovery in 1980, it was known that the genes for sublancin 168 synthesis and producer immunity were located on the SP prophage (Hemphill et al., 1980; Dorenbos et al., 2002) . However, it took about 18 years before sublancin 168 and the gene encoding this bacteriocin were identified (Paik et al., 1998) , and it remained unclear until now which of the 187 genes on the SP prophage would be required for sublancin 168 immunity. This old question has now been answered by the identification of sunI as the sublancin 168 immunity gene. Recently, it was reported that genes in the W regulon serve important functions in the protection of B. subtilis against sublancin 168 (Butcher and Helmann, 2006) . Butcher and Helmann reported that the yqeZ and yqfAB genes, which are part of the W regulon, confer sublancin 168 resistance to SP -deficient B. subtilis strains. Consistent with its protective function, the yqeZyqfAB operon is induced by sublancin 168, as is the case for the entire W regulon. Nevertheless, our present observation that the SP strain is not able to grow in a co-culture with the parental strain 168 shows that this natural W -dependent resistance mechanism provides insufficient protection for growth and survival in the presence of a sublancin 168 producing strain. In contrast, ectopic expression of sunI in the SP strain is fully sufficient to allow for growth of B. subtilis in the presence of sublancin 168, at least at the levels produced by the 168 strain. Additionally, sublancin 168 resistance was even observed in the naturally sublancin sensitive S. aureus strain RN4220 when sunI was heterologously expressed in this bacterium. The latter finding supports the view that SunI is the only B. subtilis protein required for sublancin 168 producer immunity.
So far, no studies on the biological function of SunI have been documented in the publicly available literature. Moreover, SunI does not show any significant sequence similarity to other proteins of a known function, and even small conserved sequence signatures such as a proteolytic triad appear to be absent. This makes it difficult to speculate how exactly SunI confers resistance to sublancin 168. Our topological analyses show that the SunI protein has an N out -C in orientation in the membrane with the bulk of the protein facing the cytoplasm. Strikingly, this topology has not yet been reported for known bacteriocin immunity proteins. All dedicated small bacteriocin immunity proteins have so far been detected in association with the extracytoplasmic membrane surface (Heidrich et al., 1998; Reis et al., 1994; Skaugen et al., 1997) , or are embedded in the membrane (Okuda et al., 2005; Okuda et al., 2008) . Indeed, ABC transporters involved in bacteriocin immunity do have cytoplasmic domains, but the SunI sequence does not display any similarity to known ABC transporters (Duan et al., 1996) . In fact, the topology of SunI also makes it unlikely that it functions as a transporter, which removes sublancin 168 from the membrane. Another possibility would be that SunI could function by modifying the cytoplasmic membrane to prevent entrance of sublancin 168, but this type of immunity is usually provided by larger lipoproteins at the extracytoplasmic side of the membrane (Klein and Entian, 1994; Kuipers et al., 1993) . Thus only a few possible modes of action are still conceivable for SunI, all of which differ from the known bacteriocin immunity mechanisms. For example, SunI could cooperate with a transporter in the extrusion of sublancin 168 from the membrane or cytoplasm. This putative transporter would, however, not be SunT as SunI confers sublancin resistance to B. subtilis and S. aureus strains, which lack the SunT transporter. Alternatively, SunI might block the entrance of sublancin 168 to the membrane or cytoplasm, or SunI might even protect a dedicated target of sublancin 168.
The production of sublancin 168 from a prophage (i.e. SP ) is interesting from an evolutionary perspective since the presence of the sunA gene in the phage genome ensures the maintenance of this lysogenic phage in a B. subtilis population from the moment that phage infection and chromosomal insertion has occurred. This generates a necessity for the phage also to carry the sunI gene because, otherwise, infected host cells would pass away, which would be clearly disadvantageous from a phage's perspective. From a host cell perspective, acquisition of the SP prophage is also advantageous since the production of the potent bacteriocin sublancin 168 provides this cell with a clear competitive advantage over other cells, as illustrated in our co-cultivation experiments. The chromosomal localization of sunI directly next to sunA also seems to underscore the importance of SunI for immunity. It seems likely that evolutionary selective pressure has linked these two genes closely together, which is consistent with the notion that a spontaneously occurring loss of sunI would result in a non-viable situation for strains maintaining an intact sunA gene. Nevertheless, sunI and sunA are not located in the same operon, but transcribed from different promoters (Serizawa et al., 2005) . Interestingly, sublancin 168, unlike many other bacteriocins, was recently reported to be already produced at exponential growth (Veening et al., 2008) . This is in agreement with our present data showing that SunI is continuously produced . This ensures that sublancin 168 producing cells are immune to their own bacteriocin during all stages of growth.
The reason why SunI differs from other known bacteriocin immunity determinants, especially also with respect to its topology, most likely relates to the fact that it protects against a unique type of bacteriocin. Sublancin 168 was originally classified as a type AII lantibiotic because of the presence of a methyllanthionine bridge and a leader peptide with the characteristic "double glycine" cleavage site motif of type AII lantibiotics (Paik et al., 1998) . Nevertheless, it is quite a special member of this bacteriocin subgroup (Chatterjee et al., 2005) . The two unique disulphide bonds are not encountered in other lantibiotics and give sublancin a structure that is clearly distinct from any other known type of lantibiotic. It has therefore been proposed to classify sublancin 168 to a completely different group of lantibiotics (Nagao et al., 2006) . Unfortunately, the mechanism of sublancin's bactericidal activity is presently unknown and, thus, provides no clues for a possible mechanism by which SunI provides immunity to sublancin 168. Our continuing efforts are therefore aimed at elucidating the mode of action of sublancin 168, which should also allow us to resolve the seemingly unique mechanism of producer immunity conferred by SunI.
EXPERIMENTAL PROCEDURES
Bacterial strains, plasmids and growth media
The bacterial strains and plasmids used in this study are listed in Table 1 . LB medium consisted of 1% trypton, 0.5% yeast extract and 1.0% NaCl, pH 7.4. Where necessary, media were supplemented with antibiotics at the following concentrations: ampicillin (Ap), 100 µg/ml (Escherichia coli); kanamycin (Km), 20 µg/ml (E. coli, B. subtilis, S. aureus); chloramphenicol (Cm), 5 µg/ml (E. coli and B. subtilis); tetracycline (Tc), 10 µg/ml (E. coli and B. subtilis); erythromycin (Em), 100 g/ml (E. coli), 2 g/ml (B. subtilis) or 5 g/ml (S. aureus). To visualize -amylase activity (specified by the amyE gene), LB plates were supplemented with 1% starch.
DNA techniques
Procedures for DNA amplification, restriction, ligation and transformation of E. coli DH5 and TG90 were carried out according to standard laboratory procedures (Sambrook et al., 1989) . Chromosomal DNA of B. subtilis was isolated according to Bron and Venema (Bron and Venema, 1972) . B. subtilis was transformed as described by Kunst and Rapoport (Kunst and Rapoport, 1995) . All primers used for PCR are listed in Table 2 . PCR products were purified using the High Pure PCR Purification Kit (Roche Applied Science). trpC2, yokA; yokB; yokC; yokD; yokE; yokF; yokG; yokH; yokI; yokJ; yokK; yokL; yolA; yolB; yolC; yolD; uvrX; yolF; sunA; sunT; bdbA; yolJ; bdbB; Km R This work ANC2 trpC2; yolC; yolD; uvrX; yolF; sunA; sunT; bdbA; yolJ; bdbB 
Construction of mutant strains
To construct B. subtilis mutants with deletions in the SP prophage, a "three-PCR protocol" was followed. First, the flanking regions of the deleted sequences were amplified by PCR. The primers representing the beginning and end points of the deleted sequences contained extensions that were complementary to the kanamycin resistance cassette (~900 bp) from plasmid pDG783. This cassette was amplified by PCR with the primers Kana1 and Kana2. Importantly, these primers were also complementary to extensions in the primers that represent the beginning and end points of deleted genomic sequences. In a subsequent PCR, the amplified flanking regions and the amplified kanamycin resistance cassette were fused. For this purpose, the three PCR-amplified fragments were purified and mixed in equal amounts (100ng) in a PCR mixture that also contained the distal primers of the amplified flanking regions. After 10 cycles with an optimal annealing temperature for Kana1 and Kana2, the annealing temperature was increased to the optimum for the distal primers and the PCR reaction was continued for 20 cycles. Next, B. subtilis was transformed with the kanamycin cassette fused on both sides to the amplified flanking regions, and kanamycin resistant transformants were selected on plates. The replacement of genomic sequences by the kanamycin resistance cassette in these transformants was verified by PCR.
To construct the ANC1 mutant, a ~1200 bp fragment downstream of the bdbB gene was amplified using primers ASP1 and CRP2b. Next, a ~900 bp fragment downstream of the SP prophage was amplified using primers CRP3 and ASP4. Both fragments were fused by PCR to the kanamycin resistance cassette, and the resulting product (~3000 bp) was used to transform competent B. subtilis 168 cells, resulting in the ANC1 mutant.
To construct the ANC2 mutant, a ~900 bp fragment downstream of the yolC gene was amplified using the CRP5 and ASP6 primers. The 5' sequence of the CRP5 primer was complementary to the Kana2 primer. After purification, this PCR fragment was mixed with the fragment obtained with primers ASP1 and CRP2b (see above), and the amplified kanamycin resistance cassette. The three fragments were merged in a single PCR and the resulting fragment (~3000 bp) was purified and used to transform B. subtilis 168, resulting in the ANC2 mutant.
To construct the ANC3 mutant, a 900 bp fragment upstream of the yolF gene was amplified using the pYF1 and pYF2 primers. The 5' sequence of the pYF1 primer was complementary to the Kana2 primer sequence. The amplified fragment was purified and mixed with the fragment obtained by PCR with the ASP1 and CRP2b primers, and the amplified kanamycin resistance cassette. The three fragments were merged by PCR and, after purification, ligated to plasmid pUC18 cleaved with HincII. The resulting plasmid, pUC-anc3-Km R -pYF, was used to transform competent B. subtilis cells, resulting in B. subtilis ANC3. The double cross-over integration of the kanamycin resistance cassette into the chromosome was verified by PCR using the Kana1 and ASP6 primers.
To construct B. subtilis sunA-yolF, a ~900 bp fragment downstream of the sunA gene was amplified using the pSU1 and pSU2 primers. The 5' sequence of the pSU2 primer was complementary to the Kana1 primer. After purification, this PCR fragment was mixed with the PCR fragment obtained by PCR with the pYF1 and pYF2 primers and the PCR-amplified kanamycin resistance cassette. The resulting fragment (~3000 bp) was then ligated to HincII-cleaved pUC18. The resulting plasmid, pUC-pSu-Km R -pYF, was used to transform competent B. subtilis cells, resulting in the sunA-yolF strain. Double cross-over chromosomal integration of the kanamycin cassette was verified by PCR using the Kana1 and ASP6 primers.
B. subtilis sunA was constructed by transforming B. subtilis 168 with genomic DNA of the B. subtilis JH642 sunA::Km strain (Laboratory strain: HB61664; Butcher and Helmann, 2006) and selection of kanamycin resistant transformants.
The plasmids pGDL-yolF and pGDL-yolF C were constructed as follows. The yolF gene, including its ribosomal binding site, but lacking the promoter sequences, was amplified using the Re1fw and Re2rvb primers. Both primers contained EcoRI restriction sites. The amplified fragment was ligated into the pCR ® -BluntII TOPO ® plasmid (Invitrogen, Inc.), resulting in the pCR-yolF plasmid. After EcoRI excision of yolF from pCR-yolF plasmid, the gene was ligated to the EcoRI-cleaved plasmid pGDL48. Thus, two plasmids were obtained, which contained yolF in opposite orientations. In plasmid pDGL-yolF, the yolF gene is placed under the transcriptional control of the constitutive promoter of the truncated erythromycin resistance gene of pGDL48. Plasmid pGDL-yolF C contains yolF in the opposite orientation and, consequently, the promoterless yolF gene of this plasmid will not be transcribed. The orientation and sequences of the inserts were checked by sequencing.
The B. subtilis 168 Cm strain was constructed by transformation of B. subtilis 168 with plasmid pX, and subsequent selection of transformants in which the chloramphenicol marker was integrated into the amyE gene via a double cross-over recombination event. The amylase negative phenotype of chloramphenicol resistant transformants was checked on starch-containing plates. The B. subtilis SP Tc and B. subtilis SP Tc pGDL-yolF strains were constructed by transformation of B. subtilis SP or B. subtilis SP pGDL-yolF with the plasmid pXTC. Subsequently, transformants were selected in which the tetracycline marker was integrated into the amyE gene via a double cross-over recombination event. The amylase negative phenotype of tetracycline resistant transformants was checked on starch-containing plates.
Sublancin 168 activity assay
A sublancin 168-induced B. subtilis growth inhibition assay was performed on plates essentially as described by Dorenbos et al., 2002. Briefly, indicator strains and strains to be tested for sublancin 168 production were grown overnight in LB broth containing the appropriate antibiotic(s). Overnight cultures of the indicator strains were then diluted 100-fold in LB, and 100 µl aliquots of the diluted cultures were plated on LB agar. After drying of the plates, 2 µl aliquots of undiluted overnight cultures of strains to be tested for sublancin 168 production were spotted. The plates were then incubated overnight at 37 o C, and growth inhibition of the indicator strain was analyzed the next day.
Spent medium growth experiments
B. subtilis 168 was grown in LB medium overnight. Cells were removed by centrifugation (4000 g; 10 minutes) and the supernatant was filtered with a 0.45 µm filter. The obtained spent medium was supplemented with 10x LB and sterile demineralised water to reach the desired spent medium percentage. Supplementation of the spent media with 10x LB was necessary to achieve growth of B. subtilis in the spent media.
Co-culturing of B. subtilis and S. aureus strains B. subtilis 168 Cm, B. subtilis SP Tc or B. subtilis SP Tc pGDL-yolF were grown overnight as separate cultures in LB medium. In the morning, cultures were diluted to an OD 600 of 0.05 in fresh LB medium and mixed in a 1:1 ratio, resulting in co-cultures consisting of 50% B. subtilis 168 Cm and 50% of either B. subtilis SP Tc or B. subtilis SP Tc pGDL-yolF. Upon mixing, growth was continued for eight hours. Samples for plating were taken at hourly intervals during growth. The samples thus obtained were diluted 10 4 -or 10 6 -fold, and plated on LB agar containing either chloramphenicol or tetracycline. After overnight incubation at 37 o C, chloramphenicol and tetracycline resistant colonies were counted, and numbers of colony forming units (CFU) per ml of culture of each strain at the time of sampling were calculated.
The same procedure was applied for co-culturing of B. subtilis 168 Cm with either S. aureus RN4220 Em or S. aureus RN4220 pGDL-yolF. In this case, the co-culture samples were plated on LB agar containing chloramphenicol, erythromycin or kanamycin.
SDS-PAGE and Western blotting analyses
The presence of YolF, LipA, TrxA, SipS and BdbD in cell lysates or sub-cellular fractions was assayed by Western blotting analysis using specific polyclonal antibodies. For this purpose, cellular proteins were separated by SDS-PAGE (using precast NuPAGE gels from Invitrogen), and then semidry blotted (1.25 h at 100mA per gel) onto nitrocellulose membranes (Roche Molecular Biochemicals). Specific antibodies against YolF, BdbD or TrxA of B. subtilis were raised by immunisation of rabbits (Eurogentec, Belgium) 
